Ocular immunology and inflammation · 2025
Ocular Mucous Membrane Pemphigoid: Immunomodulation in a Patient with Human Immunodeficiency Virus Infection.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Thigale Uma Yogesh, Shanbhag Swapna S, Basu Sayan, Kate Anahita
Аннотация
PURPOSE: To report the clinical course and management of a case of ocular mucous membrane pemphigoid (oMMP) in a patient with human immunodeficiency virus (HIV) infection.
METHODS: A 58-year-old gentleman presented with ocular pain, photophobia, and redness in both eyes for 2 years. He had aqueous deficient dry eye disease and was advised investigations to rule out underlying connective tissue disorders. The patient had HIV infection and was on oral anti-retroviral therapy for this condition. He was subsequently lost to follow-up and presented after 4 years with a visual acuity of counting fingers in both eyes. There was a shortening of the inferior fornices with subconjunctival fibrosis and total cataract in both eyes. A conjunctival biopsy was performed to establish the diagnosis.
RESULTS: The conjunctival biopsy revealed the presence of oMMP. After ascertaining that the systemic parameters were normal and with a CD4 count of 524 cells/mm3, the patient was started on oral methotrexate. These tests were monitored every 3 months and no adverse effects were noted. The CD4 counts were stable at the last follow-up, 1 year after the diagnosis of oMMP. There was no progression of cicatrization and the visual acuity improved with cataract surgery and scleral contact lenses to 20/50 and 20/40 in the right and left eye, respectively.
CONCLUSION: Systemic immunosuppression is essential in patients with oMMP to prevent disease progression. It can be safely instituted in patients with HIV infection via a multi-disciplinary approach with stringent monitoring of systemic parameters and CD4 counts.
METHODS: A 58-year-old gentleman presented with ocular pain, photophobia, and redness in both eyes for 2 years. He had aqueous deficient dry eye disease and was advised investigations to rule out underlying connective tissue disorders. The patient had HIV infection and was on oral anti-retroviral therapy for this condition. He was subsequently lost to follow-up and presented after 4 years with a visual acuity of counting fingers in both eyes. There was a shortening of the inferior fornices with subconjunctival fibrosis and total cataract in both eyes. A conjunctival biopsy was performed to establish the diagnosis.
RESULTS: The conjunctival biopsy revealed the presence of oMMP. After ascertaining that the systemic parameters were normal and with a CD4 count of 524 cells/mm3, the patient was started on oral methotrexate. These tests were monitored every 3 months and no adverse effects were noted. The CD4 counts were stable at the last follow-up, 1 year after the diagnosis of oMMP. There was no progression of cicatrization and the visual acuity improved with cataract surgery and scleral contact lenses to 20/50 and 20/40 in the right and left eye, respectively.
CONCLUSION: Systemic immunosuppression is essential in patients with oMMP to prevent disease progression. It can be safely instituted in patients with HIV infection via a multi-disciplinary approach with stringent monitoring of systemic parameters and CD4 counts.